Moderna vaccine reports 98.2% efficacy against severe COVID-19

Embargoed until: Publicly released: 2021-09-23 07:00

International

Photo by Mufid Majnun on Unsplash

The Moderna COVID-19 vaccine is 63 per cent effective at preventing asymptomatic infection, 93.2 per cent effective at preventing any illness and 98.2 per cent effective at preventing severe disease, according to a trial in early 2021. Just over 30,000 people were enrolled in the trial, with half receiving two doses of Moderna and half receiving a placebo. 214 people who received the vaccine had an asymptomatic infection compared to 498 in the placebo group, 55 developed COVID-19 illness compared to 744 in the placebo group and two vaccinated people had severe COVID-19 compared to 106 in the placebo group.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: Baylor College of Medicine, USA

Funder: Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427

Media Contact/s

Contact details are only visible to registered journalists.